CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to TAK

Phase 3

Development Phase

2

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Q4 '27
TAKPhase 2

Ixazomib Phase 2 Est. Readout

Ixazomib
Q4 2027~Q
CT.gov
00%
Dec '26
TAKPhase 2

Ixazomib Phase 2 Est. Readout

Ixazomib
Dec 2026~
CT.gov
00%
Drug Information

Target Indication

Multiple Myeloma

Clinical Trial

NCT02312258

Last updated: 1/8/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals
EMA11/21/2016

Ninlaro

Ninlaro in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Orphan
View on EMA
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.